This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n15http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F09%3A3944%21RIV10-MZ0-00064165/
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n8http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n7http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F09%3A3944%21RIV10-MZ0-00064165
rdf:type
skos:Concept n12:Vysledek
dcterms:description
The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFN beta)-1a in patients with relapsing multiple sclerosis (MS). The AFFIRM and SENTINEL studies showed that natalizumab was effective both as monotherapy and in combination with interferon beta (IFN beta)-1a in patients with relapsing multiple sclerosis (MS).
dcterms:title
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
skos:prefLabel
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL
skos:notation
RIV/00064165:_____/09:3944!RIV10-MZ0-00064165
n3:aktivita
n10:V
n3:aktivity
V
n3:cisloPeriodika
3
n3:dodaniDat
n7:2010
n3:domaciTvurceVysledku
n14:8895465
n3:druhVysledku
n13:J
n3:duvernostUdaju
n8:S
n3:entitaPredkladatele
n15:predkladatel
n3:idSjednocenehoVysledku
312475
n3:idVysledku
RIV/00064165:_____/09:3944
n3:jazykVysledku
n16:eng
n3:klicovaSlova
Multiple sclerosis; natalizumab; interferon beta-1a; subgroup analysis; highly active relapsing multiple sclerosis; placebo-controlled trial; double-blind; interferon beta-1a; predictive value; natural-history; disability; integrin; multicenter; pathogenesis; progression
n3:klicoveSlovo
n4:interferon%20beta-1a n4:highly%20active%20relapsing%20multiple%20sclerosis n4:multicenter n4:pathogenesis n4:natural-history n4:disability n4:double-blind n4:natalizumab n4:integrin n4:predictive%20value n4:Multiple%20sclerosis n4:placebo-controlled%20trial n4:subgroup%20analysis n4:progression
n3:kodStatuVydavatele
DE - Spolková republika Německo
n3:kontrolniKodProRIV
[4D84EAF8A249]
n3:nazevZdroje
Journal of Neurology
n3:obor
n11:FH
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
20
n3:rokUplatneniVysledku
n7:2009
n3:svazekPeriodika
256
n3:tvurceVysledku
Confavreux, C. Rudick, R. A. Panzara, M. A. Lynn, F. Hutchinson, M. Phillips, JT Stuart, W. H. Wynn, DR Radue, E. W. Galetta, SL O'Connor, PW Lublin, FD Kappos, L. Miller, DH Polman, C. H. Weinstock-Guttman, B. Wajgt, A. Calabresi, P. A. Havrdová, Eva Giovannoni, G.
n3:wos
000265732800014
s:issn
0340-5354
s:numberOfPages
11